[go: up one dir, main page]

MX2018003077A - Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica. - Google Patents

Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica.

Info

Publication number
MX2018003077A
MX2018003077A MX2018003077A MX2018003077A MX2018003077A MX 2018003077 A MX2018003077 A MX 2018003077A MX 2018003077 A MX2018003077 A MX 2018003077A MX 2018003077 A MX2018003077 A MX 2018003077A MX 2018003077 A MX2018003077 A MX 2018003077A
Authority
MX
Mexico
Prior art keywords
alcoholic steatohepatitis
diagnosing
methods
nash
evaluating non
Prior art date
Application number
MX2018003077A
Other languages
English (en)
Inventor
Darteil Raphaél
Cordonnier Geneviéve
BROZEK John
Praca Emilie
BEN SUDRIK Fouad
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2018003077A publication Critical patent/MX2018003077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención se refiere a un método para el diagnóstico de esteatohepatitis no alcohólica (NASH), para determinar la actividad, la etapa, o la severidad de NASH o para clasificar un sujeto como un posible receptor o no receptor de un tratamiento de NASH. También se refiere a un kit para implementar el método de la invención, y los compuestos para usar en un método para el tratamiento de NASH, en donde el sujeto a tratarse se identifica, evalúa o clasifica de acuerdo al método de la invención.
MX2018003077A 2015-09-14 2016-09-14 Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica. MX2018003077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306412 2015-09-14
PCT/EP2016/071727 WO2017046181A1 (en) 2015-09-14 2016-09-14 Methods for diagnosing and evaluating non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
MX2018003077A true MX2018003077A (es) 2018-05-28

Family

ID=54199140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003077A MX2018003077A (es) 2015-09-14 2016-09-14 Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica.

Country Status (19)

Country Link
US (2) US11371098B2 (es)
EP (2) EP3350341B1 (es)
JP (2) JP6947721B2 (es)
KR (1) KR102786998B1 (es)
CN (1) CN108138232B (es)
AU (1) AU2016323380B2 (es)
CA (1) CA2997336A1 (es)
DK (2) DK3712279T3 (es)
EA (1) EA201890724A1 (es)
ES (2) ES2980812T3 (es)
FI (1) FI3712279T3 (es)
HK (1) HK1255351A1 (es)
HU (2) HUE056299T2 (es)
IL (1) IL257680B2 (es)
MX (1) MX2018003077A (es)
PH (1) PH12018500513A1 (es)
PT (2) PT3712279T (es)
WO (1) WO2017046181A1 (es)
ZA (1) ZA201801630B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863035C (en) 2012-01-27 2023-08-29 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
KR102646698B1 (ko) * 2016-03-30 2024-03-12 장피트 비-알코올성 지방간염의 비침습성 진단
EP3673078A1 (en) * 2017-08-25 2020-07-01 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
MX2020002206A (es) 2017-09-08 2020-07-20 Bristol Myers Squibb Co Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
WO2019053235A1 (en) 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
WO2019053233A1 (en) * 2017-09-18 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
EP3546597A1 (en) 2018-03-28 2019-10-02 Sanofi Biomarker panel for nafld/nash
SG11202108405VA (en) 2019-02-14 2021-08-30 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
AU2020236904A1 (en) 2019-03-13 2021-08-19 Genfit Diagnosis of non-alcoholic steatohepatitis
JP7631217B2 (ja) 2019-04-10 2025-02-18 ジェンフィット 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法
CN110143890B (zh) * 2019-06-12 2020-12-22 天津科技大学 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
KR20210010100A (ko) 2019-07-19 2021-01-27 고려대학교 산학협력단 체질량지수와 자기공명영상을 이용한 비알코올성 지방간 질환 진단방법
CN110484605B (zh) * 2019-09-23 2020-07-28 中国人民解放军陆军军医大学第一附属医院 一种活细胞原位检测microRNA-34的基因及其制备方法和应用
CN110578003A (zh) * 2019-10-22 2019-12-17 安徽医科大学第二附属医院 miR-200a在制备肝癌诊断治疗试剂盒及在制备抗肿瘤药物中的应用
KR102341336B1 (ko) * 2019-11-20 2021-12-21 숙명여자대학교산학협력단 만성간질환의 예후 예측용 바이오마커 조성물
WO2022047035A2 (en) * 2020-08-28 2022-03-03 Hepgene, Inc. mRNA Biomarkers for Diagnosis of Liver Disease
JP2023548840A (ja) 2020-10-30 2023-11-21 ジェンフィット 肝線維化を診断する方法
WO2022093757A1 (en) * 2020-10-30 2022-05-05 The General Hospital Corporation Kits, reagents and methods for the assessment of liver diseases
WO2024038901A1 (ja) * 2022-08-17 2024-02-22 公益財団法人東京都医学総合研究所 肝疾患非侵襲性バイオマーカー及びこれを用いた肝疾患の検出
WO2024240863A1 (en) 2023-05-24 2024-11-28 Genfit Method of diagnostic of liver fibrosis
TW202503059A (zh) 2023-06-06 2025-01-16 法商Ｇｅｎｆｉｔ公司 多重免疫pcr的套組及方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1626279B1 (en) * 2004-08-12 2008-04-16 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
WO2007095387A2 (en) * 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
EP2359285B1 (en) * 2008-11-18 2017-01-11 Universite D'angers Non-invasive in vitro method for quantifying liver lesions
BR112012012815B8 (pt) * 2009-11-26 2021-05-25 Genfit uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico
WO2013068348A1 (en) * 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
AU2012334214A1 (en) * 2011-11-07 2014-05-22 Roche Innovation Center Copenhagen A/S Prognostic method for checking efficacy of micro RNA-122 inhibitors in HCV+ patients
EP2818549A4 (en) 2012-02-23 2015-09-02 Sumitomo Bakelite Co METHOD FOR CLASSIFYING BODY FLUID SAMPLE OF TEST
EP2684513A1 (en) * 2012-07-13 2014-01-15 Universite D'angers Method for providing reliable non-invasive diagnostic tests
WO2014049131A1 (en) * 2012-09-28 2014-04-03 Université d'Angers Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis
KR20140147920A (ko) * 2013-06-19 2014-12-31 가톨릭대학교 산학협력단 비알코올성 지방간염 감별용 바이오마커 ｍｉＲ-34ａ
CN104293908A (zh) * 2014-06-18 2015-01-21 镇江市第三人民医院 用于检测非酒精性脂肪肝的血清miRNA标志物组合及应用

Also Published As

Publication number Publication date
JP7274523B2 (ja) 2023-05-16
PT3350341T (pt) 2021-09-28
HK1255351A1 (zh) 2019-08-16
CA2997336A1 (en) 2017-03-23
EP3712279B1 (en) 2024-03-20
EP3712279A1 (en) 2020-09-23
JP6947721B2 (ja) 2021-10-13
AU2016323380B2 (en) 2023-01-05
AU2016323380A1 (en) 2018-03-29
EA201890724A1 (ru) 2018-10-31
ES2891347T3 (es) 2022-01-27
KR20180049098A (ko) 2018-05-10
US11371098B2 (en) 2022-06-28
EP3350341A1 (en) 2018-07-25
US20180265924A1 (en) 2018-09-20
IL257680A (en) 2018-04-30
EP3350341B1 (en) 2021-08-11
FI3712279T3 (fi) 2024-05-28
KR102786998B1 (ko) 2025-03-26
IL257680B2 (en) 2023-03-01
ES2980812T3 (es) 2024-10-03
ZA201801630B (en) 2019-01-30
PH12018500513A1 (en) 2018-09-24
US20220411874A1 (en) 2022-12-29
HUE056299T2 (hu) 2022-02-28
IL257680B (en) 2022-11-01
JP2021144048A (ja) 2021-09-24
DK3712279T3 (da) 2024-06-03
WO2017046181A1 (en) 2017-03-23
JP2018534542A (ja) 2018-11-22
CN108138232A (zh) 2018-06-08
NZ740279A (en) 2025-05-02
CN108138232B (zh) 2023-07-18
PT3712279T (pt) 2024-06-04
DK3350341T3 (da) 2021-09-27
HUE067269T2 (hu) 2024-10-28

Similar Documents

Publication Publication Date Title
MX2018003077A (es) Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica.
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
MX2012013256A (es) Composiciones y metodos para el tratamiento de leucemia.
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
CL2017002728A1 (es) Método para el tratamiento de cáncer
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CR10087A (es) Dispositivo y procedimientos para detección de micotoxinas.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EP3436018A4 (en) SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
GT201700163A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
FI20145492A7 (fi) Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201492284A1 (ru) Применение маркеров в диагностике и лечении рака предстательной железы
MX2016011377A (es) Metodo para diagnosticar cancer colorrectal a partir de una muestra de heces humanas por pcr cuantitativa, cebadores y equipo.
MX2016013323A (es) Uso medico de compuestos de artemisinina y agonistas de gefirina.
MX2016012667A (es) Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
CO2018013434A2 (es) Anticuerpos antifactor de la coagulación xi
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
MX2016016458A (es) Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
GT201300256A (es) Procesos para la elaboración de depsipéptidos macrocíclicos y nuevos intermediarios
NZ738100A (en) Igfbp3 and uses thereof